E.g., 06/04/2020
E.g., 06/04/2020

bioMérieux submits enhanced BIOFIRE® BCID2 Panel for FDA clearance

14 January, 2020

bioMérieux, a world leader in the field of in vitro diagnostics, announces that BioFire Diagnostics, its molecular biology affiliate, has submitted to the Food and Drug Administration for 510(k) clearance of the BIOFIRE® Blood Culture Identification 2 (BCID2) Panel. The BIOFIRE® BCID2 Panel includes several additional pathogens, an expanded list of antimicrobial resistance genes, and many revised targets compared to the existing BIOFIRE® BCID Panel.

bioMérieux – Second-Quarter 2016 Business Review

18 July, 2016

bioMérieux, a world leader in the field of in vitro diagnostics, today released its quarterly business review for the six months ended June 30, 2016.

Pioneering diagnostics